# A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease

> **NCT05111249** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 26 (actual)

## Conditions studied

- Early Manifest Huntington Disease

## Interventions

- **DRUG:** Branaplam
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05111249
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-08
- **Primary completion:** 2023-10-27
- **Final completion:** 2023-10-27
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** The trial was halted prematurely due to signs and symptoms that suggested the possibility of peripheral neuropathy. All participants who received branaplam continued to undergo routine (safety) evaluations for up to a year following their final dose
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05111249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05111249, "A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05111249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*